Efficacy of Liraglutide in Treating Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

OBJECTIVE To systematically evaluate the efficacy of liraglutide in treatment of polycystic ovary syndrome (PCOS). METHODS Cochrane Library, PubMed, Embase, Web of Science, CNKI, CBM, VIP databases, Wanfang databases were searched by computer to collect the literatures on clinical randomized controlled trials(RCTs) of liraglutide in the treatment of PCOS from inception to June 2019. Meta-analysis was performed by RevMan 5.3 software. RESULTS A total of 7 RCTs involving 450 patients were included. The results of the meta-analysis showed that, compared with the control group, there were obvious improvement in the values of body weight(SMD=-0.53, 95%CI=-0.78--0.28, P<0.000 1, I²=48%), waist circumference(SMD=-0.53, 95%CI=-0.96--0.09, P=0.02, I²=71%), body mass index(BMI)(MD=-1.88, 95%CI=-2.50--1.27, P<0.000 01, I²=84%), 2 h postprandial blood glucose(PBG)(SMD=-0.64, 95%CI=-0.88--0.40, P<0.000 01, I²=0%). However, there were no obvious differences between two groups in testosterone(SMD=0.08, 95%CI=-0.27-0.43, P=0.66, I²=57%), luteinizing hormone(LH)(SMD=-0.45, 95%CI=-1.03-0.12, P=0.12, I²=81%), homeostasis model assessment-insulin resistance (HOMA-IR)(SMD=-0.04, 95%CI=-0.59-0.51, P=0.89, I²=78%). The incidence of adverse reactions in the test group was higher than that in the control group, and the difference was statistically significant(RR=2.06, 95%CI=1.09-3.90, P=0.03, I²=62%). CONCLUSION Liraglutide in treatment of PCOS is effective in controlling body weight and reducing PBG, but there is no significant difference campared with the control group in improving sex hormone levels and controlling insulin resistance. Meanwhile, the incidence of adverse reactions in the liraglutide group is significantly higher than in the control group.